Arq. Bras. Cardiol. 2018; 111(3): 362-363
Secondary Dyslipidemia In Obese Children – Is There Evidence For Pharmacological Treatment?
DOI: 10.5935/abc.20180187
This Short Editorial is referred by the Research article "Secondary Dyslipidemia In Obese Children – Is There Evidence For Pharmacological Treatment?".
Obesity is a condition that has progressively increased throughout the world, also affecting children and adolescents, leading to high costs for health systems. Pediatric obesity is associated with dyslipidemia, oxidative stress, insulin resistance, and endothelial dysfunction, cardiovascular risk factors and components of the metabolic syndrome, and leads to adverse consequences such as early mortality and physical morbidity in adulthood in the short and long term.
Obesity-related dyslipidemia consists of increased triglycerides and free fatty acids, and decreased HDL-c (high-density cholesterol), normal or slightly increased LDL-c (low-density cholesterol), and increased VLDL-c (cholesterol of very low density). Plasma apolipoprotein B (apo B) concentrations are also frequently increased, in part due to increased hepatic production of apo B-containing lipoproteins.,
[…]
184